BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Treatment
71 results:

  • 1. pdgfra K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling.
    de Villenfagne L; Sablon A; Demoulin JB
    Sci Rep; 2024 Mar; 14(1):7204. PubMed ID: 38532028
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Avapritinib-based SAR studies unveil a binding pocket in KIT and pdgfra.
    Teuber A; Schulz T; Fletcher BS; Gontla R; Mühlenberg T; Zischinsky ML; Niggenaber J; Weisner J; Kleinbölting SB; Lategahn J; Sievers S; Müller MP; Bauer S; Rauh D
    Nat Commun; 2024 Jan; 15(1):63. PubMed ID: 38167404
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
    Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
    Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
    Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
    Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the pdgfra/MEK/ERK signaling pathway.
    Liu X; Hu Y; Xue Z; Zhang X; Liu X; Liu G; Wen M; Chen A; Huang B; Li X; Yang N; Wang J
    J Transl Med; 2023 Feb; 21(1):147. PubMed ID: 36829235
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
    Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
    Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
    Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
    ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
    Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
    Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. High frequency of pdgfra and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
    Hu W; Duan H; Zhong S; Zeng J; Mou Y
    J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
    Bonneville-Levard A; Frappaz D; Tredan O; Lavergne E; Corset V; Agrapart V; Chabaud S; Pissaloux D; Wang Q; Attignon V; Cartalat S; Ducray F; Thomas-Maisonneuve L; Honnorat J; Meyronet D; Taillandier L; Blonski M; Viari A; Baudet C; Sohier E; Lantuejoul S; Paindavoine S; Treilleux I; Rodriguez C; Pérol D; Blay JY
    Med Oncol; 2021 Nov; 39(1):4. PubMed ID: 34739635
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent pdgfra amplification and loss of CDKN2A/B.
    Deng MY; Sturm D; Pfaff E; Sill M; Stichel D; Balasubramanian GP; Tippelt S; Kramm C; Donson AM; Green AL; Jones C; Schittenhelm J; Ebinger M; Schuhmann MU; Jones BC; van Tilburg CM; Wittmann A; Golanov A; Ryzhova M; Ecker J; Milde T; Witt O; Sahm F; Reuss D; Sumerauer D; Zamecnik J; Korshunov A; von Deimling A; Pfister SM; Jones DTW
    Nat Commun; 2021 Sep; 12(1):5530. PubMed ID: 34545083
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
    Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
    J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. miR-424 induces apoptosis in glioblastoma cells and targets AKT1 and RAF1 oncogenes from the ERBB signaling pathway.
    Gheidari F; Arefian E; Adegani FJ; Kalhori MR; Seyedjafari E; Kabiri M; Teimoori-Toolabi L; Soleimani M
    Eur J Pharmacol; 2021 Sep; 906():174273. PubMed ID: 34153339
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Tesileanu CMS; van den Bent MJ; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Sabedot TS; Hoogstrate Y; von Deimling A; de Heer I; van IJcken WFJ; Brouwer RWW; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; Noushmehr H; French PJ
    Neuro Oncol; 2021 Sep; 23(9):1547-1559. PubMed ID: 33914057
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PDGF receptor mutations in human diseases.
    Guérit E; Arts F; Dachy G; Boulouadnine B; Demoulin JB
    Cell Mol Life Sci; 2021 Apr; 78(8):3867-3881. PubMed ID: 33449152
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
    Golebiewska A; Hau AC; Oudin A; Stieber D; Yabo YA; Baus V; Barthelemy V; Klein E; Bougnaud S; Keunen O; Wantz M; Michelucci A; Neirinckx V; Muller A; Kaoma T; Nazarov PV; Azuaje F; De Falco A; Flies B; Richart L; Poovathingal S; Arns T; Grzyb K; Mock A; Herold-Mende C; Steino A; Brown D; May P; Miletic H; Malta TM; Noushmehr H; Kwon YJ; Jahn W; Klink B; Tanner G; Stead LF; Mittelbronn M; Skupin A; Hertel F; Bjerkvig R; Niclou SP
    Acta Neuropathol; 2020 Dec; 140(6):919-949. PubMed ID: 33009951
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Glioblastomas harboring gene fusions detected by next-generation sequencing.
    Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
    Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.
    Miklja Z; Yadav VN; Cartaxo RT; Siada R; Thomas CC; Cummings JR; Mullan B; Stallard S; Paul A; Bruzek AK; Wierzbicki K; Yang T; Garcia T; Wolfe I; Leonard M; Robertson PL; Garton HJ; Wahl DR; Parmar H; Sarkaria JN; Kline C; Mueller S; Nicolaides T; Glasser C; Leary SE; Venneti S; Kumar-Sinha C; Chinnaiyan AM; Mody R; Pai MP; Phoenix TN; Marini BL; Koschmann C
    J Clin Invest; 2020 Oct; 130(10):5313-5325. PubMed ID: 32603316
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.